Nov 6, 2026, 4:29 PMHealthcare
Hims & Hers Stock Rallies on Eli Lilly GLP-1 Deal
Hims & Hers agreed with Eli Lilly to stop compounding GLP-1 drugs such as Zepbound, lifting HIMS shares. The feed provided limited additional deal details.
Listen to this briefingAudio briefing
Summary
Hims & Hers struck a GLP-1 agreement with Eli Lilly, according to a MarketWatch report published November 6, 2026. Under the agreement, Hims said it will not compound GLP-1 medications such as Zepbound in the future.
Hims & Hers shares rallied on the announcement, but the available feed did not quantify the move or disclose financial terms, implementation dates, or other provisions. The source provided no additional detail on the agreement.
Positives
- Hims & Hers shares rallied after the Eli Lilly agreement was reported.
- The agreement connects Hims & Hers directly with Eli Lilly in the GLP-1 market.
- Hims publicly committed to the agreement’s restriction on future GLP-1 compounding.
Risks & concerns
- Hims will not compound GLP-1 medications such as Zepbound in the future.
- The available feed disclosed no financial terms or implementation dates.
- The report did not quantify the Hims & Hers share-price rally.
- The source provided limited detail on the agreement’s broader provisions.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/hims-hers-struck-a-glp-1-deal-with-lilly-its-stock-is-rallying-d06ebe60?mod=mw_rss_topstories
Read full article

